Select Bibliography

Filter by any of these (after searching):

NCCTG-N0776

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 2 items

Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR).

Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - NCCTG-N0776

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Uhm, J. , Giannini, C. ... - - Clin. Cancer Res. - 2013

Manuscript - Primary - Primary - Neuro-Onc - NCCTG-N0776